Pharmacogenomics and risk stratification in cardiovascular care: Insights from randomized controlled trials.

🤖 Plain-English Summary

Genomics and personalized medicine are transforming cardiology by improving the assessment, diagnosis, and treatment of cardiovascular diseases (CVDs). To fully benefit from personalized cardiovascular care, future research should focus on validating genetic markers, refining risk prediction models, and overcoming barriers to widespread adoption.

🔑 Key Findings

• By understanding the genetic factors underlying CVDs, personalized treatment strategies can be developed to enhance patient outcomes and reduce the burden of cardiovascular conditions.
• The integration of genomics into clinical practice enables more precise risk assessments, early detection, and targeted interventions.
• This narrative review examines randomized clinical trials (RCTs) on genotype-guided therapies, pharmacogenomics, and personalized medicine in cardiology.

🔗 Related Resources